Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its CSF-1R small molecule inhibitor, was approved by the US FDA on November 11, 2026 for the systematic treatment of adult patients with symptomatic tenosynovial giant cell tumors whose surgical removal may lead to increased functional limitations or serious complications. This approval is Bejemer's fourth marketing approval after approval by China's NMPA, Health Canada, and the Swiss Medical Administration. Hoyu Pharmaceuticals will receive a milestone payment of $20 million when Bettermann achieves its first commercial sale in the US, and will receive a double-digit percentage royalty based on net global sales.

Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its CSF-1R small molecule inhibitor, was approved by the US FDA on November 11, 2026 for the systematic treatment of adult patients with symptomatic tenosynovial giant cell tumors whose surgical removal may lead to increased functional limitations or serious complications. This approval is Bejemer's fourth marketing approval after approval by China's NMPA, Health Canada, and the Swiss Medical Administration. Hoyu Pharmaceuticals will receive a milestone payment of $20 million when Bettermann achieves its first commercial sale in the US, and will receive a double-digit percentage royalty based on net global sales.